留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝移植治疗HIV合并HCV阳性患者的研究进展

颜曦婧 杨扬

颜曦婧, 杨扬. 肝移植治疗HIV合并HCV阳性患者的研究进展[J]. 器官移植, 2020, 11(6): 677-684. doi: 10.3969/j.issn.1674-7445.2020.06.005
引用本文: 颜曦婧, 杨扬. 肝移植治疗HIV合并HCV阳性患者的研究进展[J]. 器官移植, 2020, 11(6): 677-684. doi: 10.3969/j.issn.1674-7445.2020.06.005
Yan Xijing, Yang Yang. Research progress on the application of liver transplantation in HIV combined with HCV positive patients[J]. ORGAN TRANSPLANTATION, 2020, 11(6): 677-684. doi: 10.3969/j.issn.1674-7445.2020.06.005
Citation: Yan Xijing, Yang Yang. Research progress on the application of liver transplantation in HIV combined with HCV positive patients[J]. ORGAN TRANSPLANTATION, 2020, 11(6): 677-684. doi: 10.3969/j.issn.1674-7445.2020.06.005

肝移植治疗HIV合并HCV阳性患者的研究进展

doi: 10.3969/j.issn.1674-7445.2020.06.005
基金项目: 

国家"十三五"重大科技专项 2017ZX10203205-006-001

国家自然科学基金 81770648

广东省自然科学基金 2015A030312013

广东省科技项目 2014B030301041

广东省科技项目 2017B020209004

广州市科技项目 201400000001-3

详细信息
    作者简介:

    颜曦婧,女,1995年生,硕士研究生,研究方向为肝移植,Email:yanxj07@163.com

    通讯作者:

    杨扬,男,1971年生,博士,主任医师,研究方向为肝移植,Email:yysysu@163.com

  • 中图分类号: R617;R512.91

Research progress on the application of liver transplantation in HIV combined with HCV positive patients

More Information
  • 摘要: 随着高效抗逆转录病毒治疗(HAART)时代的到来,获得性免疫缺陷综合征(AIDS)已经从不可治愈的绝症逐渐演变为可控型慢性疾病。由于AIDS患者生命周期的延长,慢性肾衰竭和(或)慢性肝衰竭已经成为其主要的死亡原因,而慢性肝衰竭的AIDS患者往往伴有丙型肝炎病毒(HCV)感染。人类免疫缺陷病毒(HIV)感染曾被认为是肝移植的禁忌证,随着医学界认知的不断深入和手术管理经验的提高,HIV阳性肝移植受者的数量日渐上升,并且取得了较好的远期生存率。但是HIV合并HCV阳性受者肝移植术后3、5、10年生存率仍然很低。为此,本文主要总结了近年来HIV阳性患者肝移植手术的开展情况、HIV合并HCV阳性患者的疾病进程及术后丙型病毒性肝炎复发的治疗措施。

     

  • [1] MORABITO V, GROSSI P, LOMBARDINI L, et al. Solid organ transplantation in HIV+ recipients: Italian experience[J]. Transplant Proc, 2016, 48(2):424-430. DOI: 10.1016/j.transproceed.2015.12.049.
    [2] HIV in the United States and Dependent Areas[EB/OL].[2020-06-10]. https://www.cdc.gov/hiv/statistics/overview/ataglance.html.
    [3] LOCKE JE, DURAND C, REED RD, et al. Long-term outcomes after liver transplantation among human immunodeficiency virus-infected recipients[J]. Transplantation, 2016, 100(1):141-146. DOI: 10.1097/TP.0000000000000829.
    [4] BLUMBERG EA, STOCK P, AST Infectious Diseases Community of Practice. Solid organ transplantation in the HIV-infected patient[J]. Am J Transplant, 2009, 9 (Suppl 4):S131-S135. DOI: 10.1111/j.1600-6143.2009.02903.x.
    [5] STOCK PG, ROLAND ME. Evolving clinical strategies for transplantation in the HIV-positive recipient[J]. Transplantation, 2007, 84(5):563-571. DOI: 10.1097/01.tp.0000279190.96029.77.
    [6] LACOMBE K, ROCKSTROH J. HIV and viral hepatitis coinfections: advances and challenges[J]. Gut, 2012, 61(Suppl 1):i47-i58. DOI: 10.1136/gutjnl-2012-302062.
    [7] WEBER R, SABIN CA, FRⅡS-MØLLER N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study[J]. Arch Intern Med, 2006, 166(15):1632-1641. DOI: 10.1001/archinte.166.15.1632.
    [8] COOPER C, ROLLET-KURHAJEC KC, YOUNG J, et al. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients[J]. HIV Med, 2015, 16(1):24-31. DOI: 10.1111/hiv.12168.
    [9] Joint United Nations Programme on HIV/AIDS (UNAIDS). Global HIV & AIDS statistics - 2020 fact sheet[EB/OL].[2020-05-05]. http://unaids.mio.guru/en/resources/fact-sheet.
    [10] WERBEL WA, DURAND CM. Solid organ transplantation in HIV-infected recipients: history, progress, and frontiers[J]. Curr HIV/AIDS Rep, 2019, 16(3):191-203. DOI: 10.1007/s11904-019-00440-x.
    [11] BACCARANI U, RIGHI E, ADANI GL, et al. Pros and cons of liver transplantation in human immunodeficiency virus infected recipients[J]. World J Gastroenterol, 2014, 20(18):5353-5362. DOI: 10.3748/wjg.v20.i18.5353.
    [12] MURILLAS J, RIMOLA A, LAGUNO M, et al. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study[J]. Liver Transpl, 2009, 15(9):1133-1141. DOI: 10.1002/lt.21735.
    [13] VAN PILSUM RASMUSSEN SE, BOWRING MG, SHAFFER AA, et al. Knowledge, attitudes, and planned practice of HIV-positive to HIV-positive transplantation in US transplant centers[J]. Clin Transplant, 2018, 32(10):e13365. DOI: 10.1111/ctr.13365.
    [14] CAMPOS-VARELA I, DODGE JL, BERENGUER M, et al. Temporal trends and outcomes in liver transplantation for recipients with HIV infection in Europe and United States[J]. Transplantation, 2020, 104(10):2078-2086. DOI: 10.1097/TP.0000000000003107.
    [15] SORIANO V, PUOTI M, PETERS M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-hepatitis B virus international panel[J]. AIDS, 2008, 22(12):1399-1410. DOI: 10.1097/QAD.0b013e3282f8b46f.
    [16] SULKOWSKI MS. Management of hepatic complications in HIV-infected persons[J]. J Infect Dis, 2008, 197(Suppl 3):S279-S293. DOI: 10.1086/533414.
    [17] OCKENGA J, TILLMANN HL, TRAUTWEIN C, et al. Hepatitis B and C in HIV-infected patients. prevalence and prognostic value[J]. J Hepatol, 1997, 27(1):18-24. DOI: 10.1016/s0168-8278(97)80274-7.
    [18] STAPLES CT JR, RIMLAND D, DUDAS D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival[J]. Clin Infect Dis, 1999, 29(1):150-154. DOI: 10.1086/520144.
    [19] SORIANO V, GARCÍA-SAMANIEGO J, BRAVO R, et al. Morbidity and mortality associated with chronic viral hepatopathy in patients infected with the human immunodeficiency virus[J]. Med Clin (Barc), 1995, 104(17):641-644. http://www.ncbi.nlm.nih.gov/pubmed/7623489
    [20] BENHAMOU Y, BOCHET M, DI MARTINO V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. the multivirc group[J]. Hepatology, 1999, 30(4):1054-1058. DOI: 10.1002/hep.510300409.
    [21] PINEDA JA, ROMERO-GÓMEZ M, DÍAZ-GARCÍA F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis[J]. Hepatology, 2005, 41(4):779-789. DOI: 10.1002/hep.20626.
    [22] PINEDA JA, GARCÍA-GARCÍA JA, AGUILAR-GUISADO M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy[J]. Hepatology, 2007, 46(3):622-630. DOI: 10.1002/hep.21757.
    [23] GARBA ML, PILCHER CD, BINGHAM AL, et al. HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8+ T cells[J]. J Immunol, 2002, 168(5):2247-2254. DOI: 10.4049/jimmunol.168.5.2247.
    [24] 隋国德, 程广, 袁俊俊, 等. IL-13 PGE2 PGI2通过PKC通路活化肝星形细胞参与肝脏纤维化作用研究[J].现代医药卫生, 2017, 33(17):2591-2595. DOI: 10.3969/j.issn.1009-5519.2017.17.005.

    SUI GD, CHENG G, YUAN JJ, et al. Role of IL-13, PGE2 and PGI2 for participating in hepatic fibrosis by activating hepatic stellate cells through PKC path-way[J]. J Mod Med Health, 2017, 33(17):2591-2595. DOI: 10.3969/j.issn.1009-5519.2017.17.005.
    [25] 王甘露, 邵圣文, 徐伯赢, 等.丙型肝炎病毒F蛋白上调肝星形细胞胶原表达[J].中国普外基础与临床杂志, 2010, 17(12):1258-1260. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgpwjcylczz201012009

    WANG GL, SHAO SW, XU BY, et al. Up-regulation of collagen expression in hepatic stellate cells by F protein of hepatitis C virus[J]. Chin J Base Clin General Sur, 2010, 17(12):1258-1260. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgpwjcylczz201012009
    [26] SAFADI R, OHTA M, ALVAREZ CE, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes[J]. Gastroenterology, 2004, 127(3):870-882. DOI: 10.1053/j.gastro.2004.04.062.
    [27] 王思奇.肝脏免疫微环境与肝纤维化的研究进展[J].复旦学报(医学版), 2018, 45(5):727-734. DOI: 10.3969/j.issn.1672-8467.2018.05.021.

    WANG SQ. Research progress in liver immune microenvironment and liver fibrosis[J]. Fudan Univ J Med Sci, 2018, 45(5):727-734. DOI: 10.3969/j.issn.1672-8467.2018.05.021.
    [28] WEN J, ZHOU Y, WANG J, et al. Interactions between Th1 cells and Tregs affect regulation of hepatic fibrosis in biliary atresia through the IFN-γ/STAT1 pathway[J]. Cell Death Differ, 2017, 24(6):997-1006. DOI: 10.1038/cdd.2017.31.
    [29] HSU YC, LIN JT, HO HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients[J]. Hepatology, 2014, 59(4):1293-1302. DOI: 10.1002/hep.26892.
    [30] CARVALHO RF, ATTA AM, DE OLIVEIRA IS, et al. Adiponectin levels and insulin resistance among patients with chronic hepatitis C[J]. Acta Trop, 2018, 178:258-263. DOI: 10.1016/j.actatropica.2017.12.004.
    [31] BLANCO F, BARREIRO P, RYAN P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance[J].J Viral Hepat, 2011, 18(1):11-16. DOI: 10.1111/j.1365-2893.2009.01261.x.
    [32] GANESAN M, POLUEKTOVA LY, KHARBANDA KK, et al. Liver as a target of human immunodeficiency virus infection[J]. World J Gastroenterol, 2018, 24(42):4728-4737. DOI: 10.3748/wjg.v24.i42.4728.
    [33] MORENO A, CERVERA C, FORTÚN J, et al. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study[J]. Liver Transpl, 2012, 18(1):70-81. DOI: 10.1002/lt.22431.
    [34] HONG F, SAIMAN Y, SI C, et al. X4 human immunodeficiency virus type 1 gp120 promotes human hepatic stellate cell activation and collagen I expression through interactions with CXCR4[J]. PLoS One, 2012, 7(3):e33659. DOI: 10.1371/journal.pone.0033659.
    [35] DAGUR RS, WANG W, CHENG Y, et al. Human hepatocyte depletion in the presence of HIV-1 infection in dual reconstituted humanized mice[J]. Biol Open, 2018, 7(2):bio029785. DOI: 10.1242/bio.029785.
    [36] MUNSHI N, BALASUBRAMANIAN A, KOZIEL M, et al. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism[J]. J Infect Dis, 2003, 188(8):1192-1204. DOI: 10.1086/378643.
    [37] JANG JY, SHAO RX, LIN W, et al. HIV infection increases HCV-induced hepatocyte apoptosis[J]. J Hepatol, 2011, 54(4):612-620. DOI: 10.1016/j.jhep.2010.07.042.
    [38] BRUNO R, GALASTRI S, SACCHI P, et al. gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis[J]. Gut, 2010, 59(4):513-520. DOI: 10.1136/gut.2008.163287.
    [39] VALI B, YUE FY, JONES RB, et al. HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection[J]. PLoS One, 2008, 3(10):e3454. DOI: 10.1371/journal.pone.0003454.
    [40] SANDLER NG, DOUEK DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities[J]. Nat Rev Microbiol, 2012, 10(9):655-666. DOI: 10.1038/nrmicro2848.
    [41] GE D, FELLAY J, THOMPSON AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J]. Nature, 2009, 461(7262):399-401. DOI: 10.1038/nature08309.
    [42] RALLÓN NI, NAGGIE S, BENITO JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients[J]. AIDS, 2010, 24(8):F23-F29. DOI: 10.1097/QAD.0b013e3283391d6d.
    [43] MANZARDO C, LONDOÑO MC, CASTELLS L, et al. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: a prospective nationwide cohort study[J]. Am J Transplant, 2018, 18(10):2513-2522. DOI: 10.1111/ajt.14996.
    [44] TANAKA T, AKAMATSU N, KANEKO J, et al. Daclatasvir and asunaprevir for recurrent hepatitis C following living donor liver transplantation with HIV co-infection[J]. Hepatol Res, 2016, 46(8):829-832. DOI: 10.1111/hepr.12614.
    [45] DUCLOS-VALLÉE JC, FÉRAY C, SEBAGH M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus[J]. Hepatology, 2008, 47(2):407-417. DOI: 10.1002/hep.21990.
    [46] MIRO JM, MONTEJO M, CASTELLS L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study[J]. Am J Transplant, 2012, 12(7):1866-1876. DOI: 10.1111/j.1600-6143.2012.04028.x.
    [47] TERRAULT NA, ROLAND ME, SCHIANO T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection[J]. Liver Transpl, 2012, 18(6):716-726. DOI: 10.1002/lt.23411.
    [48] MIRO JM, STOCK P, TEICHER E, et al. Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. a 2015 update[J]. J Hepatol, 2015, 62(3):701-711. DOI: 10.1016/j.jhep.2014.10.032.
    [49] KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2):464-470. DOI: 10.1053/jhep.2001.22172.
    [50] SULKOWSKI MS. Viral hepatitis and HIV coinfection[J]. J Hepatol, 2008, 48(2):353-367. DOI: 10.1016/j.jhep.2007.11.009.
    [51] FERRARESE A, ZANETTO A, GAMBATO M, et al. Liver transplantation for viral hepatitis in 2015[J]. World J Gastroenterol, 2016, 22(4):1570-1581. DOI: 10.3748/wjg.v22.i4.1570.
    [52] TE HS. Recurrent hepatitis C: the bane of transplant hepatology[J]. Hepatology, 2014, 59(1):21-23. DOI: 10.1002/hep.26591.
    [53] BERENGUER M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin[J]. J Hepatol, 2008, 49(2):274-287. DOI: 10.1016/j.jhep.2008.05.002.
    [54] DUCLOS-VALLEE JC, TATEO M, TEICHER E, et al. Results of liver transplantation in a large cohort of more than 100 HIV infected patients - a monocentric experience[J]. Hepatology, 2011, 54(suppl 4):361A. http://www.researchgate.net/publication/295927763_Results_of_Liver_Transplantation_in_a_Large_Cohort_of_More_Than_100_HIV_Infected_Patients_-_A_Monocentric_Experience
    [55] TERRAULT N, REDDY KR, POORDAD F, et al. Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients[J]. Am J Transplant, 2014, 14(5):1129-1135. DOI: 10.1111/ajt.12668.
    [56] CASTELLS L, RIMOLA A, MANZARDO C, et al. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study[J]. J Hepatol, 2015, 62(1):92-100. DOI: 10.1016/j.jhep.2014.07.034.
    [57] PELLICELLI AM, MONTALBANO M, LIONETTI R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late[J]. Dig Liver Dis, 2014, 46(10):923-927. DOI: 10.1016/j.dld.2014.06.004.
    [58] ANTONINI TM, FURLAN V, TEICHER E, et al. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation[J]. AIDS, 2015, 29(1):53-58. DOI: 10.1097/QAD.0000000000000516.
    [59] 李俊利, 尚佳, 宁会彬.直接抗病毒药物时代特殊人群HCV感染的管理和治疗[J].临床肝胆病杂志, 2018, 34(2):242-245. DOI: 10.3969/j.issn.1001-5256.2018.02.005.

    LI JL, SHANG J, NING HB. Management and treatment of special populations with hepatitis C virus infection in the era of direct-acting antiviral agents[J]. J Clin Hepatol, 2018, 34(2):242-245. DOI: 10.3969/j.issn.1001-5256.2018.02.005.
    [60] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018[J]. J Hepatol, 2018, 69(2):461-511. DOI: 10.1016/j.jhep.2018.03.026.
    [61] HOUSSEL-DEBRY P, COILLY A, FOUGEROU-LEURENT C, et al. 12 weeks of a ribavirin-free sofosbuvir and nonstructural protein 5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation[J]. Hepatology, 2018, 68(4):1277-1287. DOI: 10.1002/hep.29918.
    [62] SALCEDO M, PRIETO M, CASTELLS L, et al. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. role of cirrhosis and genotype 3. a multicenter cohort study[J]. Transpl Int, 2017, 30(10):1041-1050. DOI: 10.1111/tri.12999.
    [63] REAU N, KWO PY, RHEE S, et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection[J]. Hepatology, 2018, 68(4):1298-1307. DOI: 10.1002/hep.30046.
    [64] CHEN JY, FEENEY ER, CHUNG RT. HCV and HIV co-infection: mechanisms and management[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(6):362-371. DOI: 10.1038/nrgastro.2014.17.
    [65] BULTEEL N, LEEN C. Editorial: direct-acting anti-virals-not the be-all and end-all in HIV/HCV co-infection[J]. Aliment Pharmacol Ther, 2017, 45(4):569-570. DOI: 10.1111/apt.13884.
    [66] SCHLABE S, ROCKSTROH JK. Advances in the treatment of HIV/HCV coinfection in adults[J]. Expert Opin Pharmacother, 2018, 19(1):49-64. DOI: 10.1080/14656566.2017.1419185.
    [67] 李雯彬, 张文杰, 张晓瑛, 等.直接抗病毒药物时代下丙型病毒性肝炎的研究现状[J].中国中西医结合消化杂志, 2018, 26(10):886-891. DOI: 10.3969/j.issn.1671-038X.2018.10.19.

    LI WB, ZHANG WJ, ZHANG XY, et al. Research status of hepatitis C virus in the era of liver direct antiviral drugs[J]. Chin J Integr Trad West Med Dig, 2018, 26(10):886-891. DOI: 10.3969/j.issn.1671-038X. 2018.10.19.
  • 加载中
计量
  • 文章访问数:  131
  • HTML全文浏览量:  73
  • PDF下载量:  18
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-07-20
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2021-01-19

目录

    /

    返回文章
    返回